Latest Advances in Aging Research and Drug Discovery
View / Open Files
Authors
Publication Date
2019-11-21Journal Title
Aging
ISSN
1945-4589
Publisher
Impact Journals
Volume
11
Issue
22
Pages
9971-9981
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Rubinsztein, D. (2019). Latest Advances in Aging Research and Drug Discovery. Aging, 11 (22), 9971-9981. https://doi.org/10.18632/aging.102487
Abstract
An increasing aging population poses a significant challenge to societies worldwide. A better understanding of the molecular, cellular, organ, tissue, physiological, psychological, and even sociological changes that occur with aging is needed in order to treat age-associated diseases. The field of aging research is rapidly expanding with multiple advances transpiring in many previously disconnected areas. Several major pharmaceutical, biotechnology, and consumer companies made aging research a priority and are building internal expertise, integrating aging research into traditional business models and exploring new go-to-market strategies. Many of these efforts are spearheaded by the latest advances in artificial intelligence, namely deep learning, including generative and reinforcement learning. To facilitate these trends, the Center for Healthy Aging at the University of Copenhagen and Insilico Medicine are building a community of Key Opinion Leaders (KOLs) in these areas and launched the annual conference series titled “Aging Research and Drug Discovery (ARDD)” held in the capital of the pharmaceutical industry, Basel, Switzerland (www.agingpharma.org). This ARDD collection contains summaries from the 6th annual meeting that explored aging mechanisms and new interventions in age-associated diseases. The 7th annual ARDD exhibition will transpire 2nd-4th of September, 2020, in Basel.
Keywords
aging, artificial intelligence, drug discovery, Aging, Drug Discovery, Drug Industry, Humans, Research
Sponsorship
DB is supported by the German Research Foundation
(Forschungsstipendium; BA 6276/1-1) and the
Lundbeckfonden (#R303-2018-3159). DC is funded by
the NIH (R01AG 063389, R01AG063404,
R01DK117481, R01DK101885) and the NIFA. VNG is
supported by NIH grants. AT is supported by the
Russian Federation grant 14.W03.31.0012. TH is
supported by the Deutsche Forschungsgemeinschaft
(DFG) (CECAD) and the European Research Council
(consolidator grant 616499). DCR is grateful for
funding from the UK Dementia Research Institute
(funded by the MRC, Alzheimer’s Research UK and the
Alzheimer’s Society) (DCR), an anonymous donation to
the Cambridge Centre for Parkinson-Plus, The
Rosetrees Trust, The Tau Consortium and The Roger de
Spoelberch Foundation (DCR). MSK is funded by the
Nordea Foundation (#02-2017-1749), the Novo Nordisk
Foundation (#NNF17OC0027812), the Danish Cancer
Society (#R167-A11015_001), the Independent
Research Fund Denmark (#7016-00230B), the Neye
Foundation and Insilico Medicine.
Identifiers
External DOI: https://doi.org/10.18632/aging.102487
This record's URL: https://www.repository.cam.ac.uk/handle/1810/298873
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk